GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Xanomeline/trospium (COBENFY)

Local official-label summaryBase record retrieved 2026-09-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

COBENFY

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

A fixed-combination renal restriction is not single-agent trospium dosing

The mirror and January 2026 label agree on the selected renal restriction. Both print MDRD-associated eGFR in mL/min without an indexing denominator.

Before applying: Retain exact printed units, renal wording and the separate urinary-retention contraindication; do not improvise a component-based workaround.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Xanomeline / trospium - COBENFY oral capsules

Product / population
COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.
Renal measure
MDRD eGFR; printed mL/min units retained without conversion
Before using this finding

Not recommended, contraindicated and dose-reduced are different instructions.

The printed MDRD units were not silently normalized.

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Renal dosing, restrictions and evidence limits

The January 2026 label uses the same dosage as normal renal function for mild impairment (printed eGFR 60 to <90 mL/min). Below 60 mL/min, COBENFY is not recommended; increased anticholinergic effects are expected as trospium exposure rises.

Pre-existing urinary retention is a separate contraindication. Do not reinterpret the renal wording as either a universal contraindication or permission to improvise a reduced fixed-combination regimen. The renal PK section specifies MDRD while printing mL/min; the indexing question remains explicit. No dialysis dose is established by these selected sections.

Source revision: 1/2026 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f0e73bf-6025-44f6-ab64-0983322de0df

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Xanomeline / trospium - COBENFY oral capsules

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - COBENFY

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Xanomeline / trospium - COBENFY oral capsules

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Not recommended, contraindicated and dose-reduced are different instructions.

The printed MDRD units were not silently normalized.

Dialysis evidence: No dialysis regimen established in selected content

COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.

Renal method: MDRD eGFR; printed mL/min units retained without conversion
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - COBENFY

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Adults with schizophrenia; fixed oral xanomeline/trospium product. Not Sanctura or trospium monotherapy.

Renal method: eGFR printed as mL/min; denominator/method reconciliation required.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - COBENFY

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Confirm renal measure and complete fixed combination.

Dialysis evidence: No dialysis regimen established in selected content

COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.

Renal method: MDRD eGFR; source prints mL/min, indexing requires reconciliation
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A fixed-combination renal restriction is not single-agent trospium dosing

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

selected concordance with metric qualification

A fixed-combination renal restriction is not single-agent trospium dosing

The mirror and January 2026 label agree on the selected renal restriction. Both print MDRD-associated eGFR in mL/min without an indexing denominator.

How to use this: Retain exact printed units, renal wording and the separate urinary-retention contraindication; do not improvise a component-based workaround.

GlobalRPh RX List - COBENFYXanomeline / trospium - COBENFY oral capsules

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeXanomeline / trospium - COBENFY oral capsulesGlobalRPh RX List - COBENFYGlobalRPh RX List - COBENFY
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/cobenfy-drug/

Exact product and population

Adults with schizophrenia; fixed oral xanomeline/trospium product. Not Sanctura or trospium monotherapy.

RDM35-SCOPE-xanomeline-trospium-cobenfy · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Xanomeline / trospium - COBENFY oral capsules

Open original reference

Open / share this exact local source

DailyMed · COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.

Renal method: MDRD eGFR; printed mL/min units retained without conversion
Source date: 1/2026
Retrieved: 2026-09-10

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Not recommended, contraindicated and dose-reduced are different instructions.

The printed MDRD units were not silently normalized.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The January 2026 label uses the same dosage as normal renal function for mild impairment (printed eGFR 60 to <90 mL/min). Below 60 mL/min, COBENFY is not recommended; increased anticholinergic effects are expected as trospium exposure rises.

Pre-existing urinary retention is a separate contraindication. Do not reinterpret the renal wording as either a universal contraindication or permission to improvise a reduced fixed-combination regimen. The renal PK section specifies MDRD while printing mL/min; the indexing question remains explicit. No dialysis dose is established by these selected sections.

RDM59-official-xanomeline-trospium-cobenfy-8f18776f30-C1 · Source locator: Sections 8.6, 5.8, 4, 5.1 and 12.3

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f0e73bf-6025-44f6-ab64-0983322de0df
Retrieved
2026-09-10
Exact label title
Xanomeline / trospium - COBENFY oral capsules
DailyMed Set ID
8f0e73bf-6025-44f6-ab64-0983322de0df
Label revision
1/2026
Renal-function method
MDRD eGFR; printed mL/min units retained without conversion
Source date/version
1/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b899c0afd049e006da3ce228d856cb856b176e064a191cc4493d02954ceabd9b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - COBENFY

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults with schizophrenia; fixed oral xanomeline/trospium product. Not Sanctura or trospium monotherapy.

Renal method: eGFR printed as mL/min; denominator/method reconciliation required.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Mild renal impairment (source eGFR 60 to <90 mL/min): the recommended dose is unchanged despite increased component exposures in pharmacokinetic assessment. Use is not recommended when eGFR is below 60. Urinary-retention risk and the geriatric titration limits remain relevant; this is not the renal schedule for trospium used alone. The retrieved renal section prints eGFR in mL/min without an indexed denominator. Verify the exact current product-label method and units near a decision boundary rather than assuming equivalence to Cockcroft-Gault or an indexed laboratory result.

RDM35-rxlist-xanomeline-trospium-cobenfy-74c2c65b01-C1 · Source locator: Renal impairment; dosage; warnings; pharmacokinetics, as identified in the selected retrieval.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cobenfy-drug/
Retrieved
2026-09-07
Renal-function method
eGFR printed as mL/min; denominator/method reconciliation required.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
8cb57f041316e17bb97fcd47de655a39164205bfb6c350cbb9505731316e01d8
Rxlist

GlobalRPh RX List - COBENFY

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · COBENFY fixed combination for schizophrenia in adults; not interchangeable with single-ingredient trospium bladder dosing.

Renal method: MDRD eGFR; source prints mL/min, indexing requires reconciliation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Confirm renal measure and complete fixed combination.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror retains the usual dose in mild impairment (printed eGFR 60 to <90 mL/min), while use below 60 is not recommended. Increased component exposure can increase anticholinergic effects, including urinary retention. The selected PK section identifies MDRD as the estimation method.

The source prints mL/min without the body-surface-area denominator ordinarily associated with MDRD. Preserve the printed units and method as a reconciliation question, not a silent conversion to Cockcroft-Gault. A lower single-agent trospium dose is not a supported fixed-combination workaround.

RDM59-rxlist-xanomeline-trospium-cobenfy-74c2c65b01-C1 · Source locator: Renal Impairment; Anticholinergic Adverse Reactions; renal PK

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cobenfy-drug/
Retrieved
2026-09-10
Renal-function method
MDRD eGFR; source prints mL/min, indexing requires reconciliation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
304bf5a7185b921ce1ac8bc9975469d16b1c76f87513fc0425eedf6e34341c99

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/cobenfy-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
efce9b496dce899e18b58a50aa263d2ee695693e7aedcf3127619e0684863bcf
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report